对于晚期肾上腺皮质癌所致库欣综合征，在化疗加米托坦的基础上加用美替拉酮。 - Suppr

Adding metyrapone to chemotherapy plus mitotane for Cushing's syndrome due to advanced adrenocortical carcinoma.

作者信息

Claps Mélanie, Cerri Sara, Grisanti Salvatore, Lazzari Barbara, Ferrari Vittorio, Roca Elisa, Perotti Paola, Terzolo Massimo, Sigala Sandra, Berruti Alfredo

机构信息

Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, ASST Spedali Civili di Brescia, University of Brescia, Brescia, Italy.

Internal Medicine 1, Department of Clinical and Biological Sciences, S. Luigi Hospital, University of Turin, Torino, Italy.

出版信息

Endocrine. 2018 Jul;61(1):169-172. doi: 10.1007/s12020-017-1428-9. Epub 2017 Oct 10.

DOI:10.1007/s12020-017-1428-9

PMID:29019062

Abstract

摘要

相似文献

Adding metyrapone to chemotherapy plus mitotane for Cushing's syndrome due to advanced adrenocortical carcinoma.

Endocrine. 2018 Jul;61(1):169-172. doi: 10.1007/s12020-017-1428-9. Epub 2017 Oct 10.

Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome.

J Clin Endocrinol Metab. 2011 Sep;96(9):2796-804. doi: 10.1210/jc.2011-0536. Epub 2011 Jul 13.

Adrenocortical Carcinoma with Hypercortisolism.

Endocrinol Metab Clin North Am. 2018 Jun;47(2):395-407. doi: 10.1016/j.ecl.2018.02.003. Epub 2018 Apr 9.

Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer.

Eur Urol. 2014 Apr;65(4):832-8. doi: 10.1016/j.eururo.2013.11.006. Epub 2013 Nov 14.

[Studies on drug therapy of Cushing's syndrome].

Verh Dtsch Ges Inn Med. 1977;83:1337-40.

Cushing's syndrome due to adrenocortical carcinoma - a comphrensive clinical and biochemical study of patients treated by surgery and chemotherapy.

Acta Endocrinol (Copenh). 1979 Jun;91(2):303-18. doi: 10.1530/acta.0.0910303.

Efficacy and tolerance of osilodrostat in patients with Cushing's syndrome due to adrenocortical carcinomas.

Eur J Endocrinol. 2022 Jan 6;186(2):K1-K4. doi: 10.1530/EJE-21-1008.

Feminizing adrenocortical carcinoma with Cushing's syndrome and pseudohyperparathyroidism.

Arch Intern Med. 1978 Feb;138(2):301-3.

Cushing's syndrome due to an adrenocortical carcinoma.

Postgrad Med J. 2003 Aug;79(934):466. doi: 10.1136/pmj.79.934.466.

Metastatic adrenocortical carcinoma presenting simultaneously with Cushing's and Conn's syndromes: a case report.

Jpn J Clin Oncol. 2011 Nov;41(11):1287-91. doi: 10.1093/jjco/hyr144. Epub 2011 Oct 6.

引用本文的文献

An Aggressive Case of Adrenocortical Carcinoma Complicated by Paraneoplastic Cushing's Syndrome.

Cureus. 2023 Jan 23;15(1):e34099. doi: 10.7759/cureus.34099. eCollection 2023 Jan.

Advanced Adrenocortical Carcinoma: From Symptoms Control to Palliative Care.

Cancers (Basel). 2022 Nov 29;14(23):5901. doi: 10.3390/cancers14235901.

Cushing's syndrome: a combined treatment with etomidate and osilodrostat in severe life-threatening hypercortisolemia.

Hormones (Athens). 2022 Dec;21(4):735-742. doi: 10.1007/s42000-022-00397-4. Epub 2022 Sep 21.

Metyrapone Versus Osilodrostat in the Short-Term Therapy of Endogenous Cushing's Syndrome: Results From a Single Center Cohort Study.

Front Endocrinol (Lausanne). 2022 Jun 13;13:903545. doi: 10.3389/fendo.2022.903545. eCollection 2022.

Supportive therapies in patients with advanced adrenocortical carcinoma submitted to standard EDP-M regimen.

Endocrine. 2022 Sep;77(3):438-443. doi: 10.1007/s12020-022-03075-y. Epub 2022 May 14.

Case Report: Exceptional Response to Second Line Temozolomide Therapy in a Patient With Metastatic Adrenocortical Carcinoma.

Front Endocrinol (Lausanne). 2021 Apr 22;12:674039. doi: 10.3389/fendo.2021.674039. eCollection 2021.

Efficacy of the EDP-M Scheme Plus Adjunctive Surgery in the Management of Patients with Advanced Adrenocortical Carcinoma: The Brescia Experience.

Cancers (Basel). 2020 Apr 10;12(4):941. doi: 10.3390/cancers12040941.

Low-dose etomidate for the management of severe hypercortisolaemia in different clinical scenarios: a case series and review of the literature.

Ther Adv Endocrinol Metab. 2019 Feb 8;10:2042018819825541. doi: 10.1177/2042018819825541. eCollection 2019.

Management of Adrenocortical Carcinoma.

Curr Oncol Rep. 2019 Feb 23;21(3):20. doi: 10.1007/s11912-019-0773-7.

Advances in adrenal tumors 2018.

Endocr Relat Cancer. 2018 Jul;25(7):R405-R420. doi: 10.1530/ERC-18-0138.

本文引用的文献

The first description of metyrapone use in severe Cushing Syndrome due to ectopic ACTH secretion in an infant with immature sacrococcygeal teratoma. Case Report.

Neuro Endocrinol Lett. 2015 Dec;36(7):653-5.

Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients.

J Clin Endocrinol Metab. 2015 Nov;100(11):4146-54. doi: 10.1210/jc.2015-2616. Epub 2015 Sep 9.

Evolution in functionality of a metastatic pancreatic neuroendocrine tumour (pNET) causing Cushing's syndrome: treatment response with chemotherapy.

BMC Endocr Disord. 2014 Aug 24;14:70. doi: 10.1186/1472-6823-14-70.

Management of adrenal cancer: a 2013 update.

J Endocrinol Invest. 2014 Mar;37(3):207-17. doi: 10.1007/s40618-013-0049-2.

Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer.

Eur Urol. 2014 Apr;65(4):832-8. doi: 10.1016/j.eururo.2013.11.006. Epub 2013 Nov 14.

Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2012 Oct;23 Suppl 7:vii131-8. doi: 10.1093/annonc/mds231.

Combination chemotherapy in advanced adrenocortical carcinoma.

N Engl J Med. 2012 Jun 7;366(23):2189-97. doi: 10.1056/NEJMoa1200966. Epub 2012 May 2.

Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma.

Clin Endocrinol (Oxf). 2011 Nov;75(5):585-91. doi: 10.1111/j.1365-2265.2011.04214.x.

Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study.

J Clin Endocrinol Metab. 2011 Jun;96(6):1844-51. doi: 10.1210/jc.2010-2676. Epub 2011 Apr 6.

Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma.

Endocr Relat Cancer. 2010 Aug 16;17(3):797-807. doi: 10.1677/ERC-09-0341. Print 2010 Sep.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Adding metyrapone to chemotherapy plus mitotane for Cushing's syndrome due to advanced adrenocortical carcinoma.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献